Greetings, Alpha traders! As we head toward the middle of the week, it’s time to take a look at three stock selections that we’ve been tracking. This week, the focus has been on three biotechnology sector stocks, and we will continue to monitor the price movement of these three picks.
By the end of the week, we will select a winner based on best price performance percentage-wise, and this winner shall be called the Alpha. Until that time, we can perform a checkup on our selections from biotechnology sector. So, let’s see exactly how they’re doing!
The first biotech stock selection this week is Zafgen, Inc. (ZFGN). Zafgen, Inc. is based in Boston, Massachusetts, and is a clinical-stage biopharmaceutical company which develops therapies for patients suffering from a range of ailments including diabetes and Prader-Willi syndrome.
It wasn’t long ago that Zafgen first initiated an underwritten public offering of its common stock, so this stock could prove to be a ground-floor opportunity. ZFGN stock shares finish at $9.51 at the end of last week, and when the closing bell rang on Tuesday, the shares were trading at $9.41, representing a loss of 1%. I wouldn’t call this a terrible loss, and there’s still time for Zafgen to show some strength this week.
Now we’ll check on the next biotech stock selection, Ultragenyx Pharmaceutical Inc. (RARE). Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California, and is a biopharmaceutical firm that focuses on the various products to treat rare genetic diseases.
Stock shares of RARE closed at $71.81 at the close of last week’s trading, and when the market hours ended on Tuesday, the shares cost $77.38, signifying a gain of 7.75%. This puts Ultragenyx Pharmaceutical Inc. firmly in the lead in the race to become this week’s Alpha stock.
Last but not least, it’s time to look at our third biotech stock selection, Viking Therapeutics, Inc. (VKTX). Viking Therapeutics, Inc. is located in San Diego, California, and is a biopharmaceutical firm focused on the development of therapies for metabolic and endocrine disorders.
VKTX stock shares ended last week’s trading at $10.25, and when trading finished on Tuesday, the shares were priced at $10.57, for a gain of 3%. That might not be as big a move as what we’re seeing with RARE, but it’s certainly nothing to sneeze at.
Inside Alpha is closely watching these three biotechnology sector picks and will continue to keep you updated on their developments. Very soon you’ll be hearing from us once again as we declare the best performer among them: the Alpha!